Description
Strategy and project management is very important in the pharmaceutical and biotechnology industries as it can take a decade and over a billion dollars to develop a successful drug. This comprehensive volume presents academic, industry and other complementary viewpoints on the drug research process with many illustrative examples, anecdotes and representative case studies. Experts evaluate the strengths and weaknesses of old and new methods, the crossroads of tactics and strategy and market forces. Project management chapters highlight decisions that must be made along the drug discovery pathway and investigate outsourcing, licensing, innovation and managing scientists. The volume concludes with some case studies so that readers can examine practical applications of strategy and project management applied to real life examples.
Readership
For students and researchers in chemistry, biochemistry, medicinal chemistry and pharmacology and scientists working in the pharmaceutical industries.
Comprehensive Medicinal Chemistry II, 1st Edition
Volume 2 Strategy and Drug Research
Introduction
2.01 The Intersection of Strategy and Drug Research
2.02 An Academic Perspective
2.03 An Industry Perspective
Organizational Aspects and Strategies for Drug Discovery and Development
2.04 Project Management
2.05 The Role of the Chemical Development, Quality, and Regulatory Affairs Teams in Turning a Potent Agent into a Registered Product
2.06 Drug Development
2.07 In-House or Out-Source
2.08 Pharma versus Biotech: Contracts, Collaborations, and Licensing
2.09 Managing Scientists, Leadership Strategies in Science
2.10 Innovation (Fighting against the Current)
2.11 Enabling Technologies in Drug Discovery: The Technical and Cultural Integration of the New with the Old
2.12 How and Why to Apply the Latest Technology
2.13 How and When to Apply Absorption, Distribution, Metabolism, Excretion, and Toxicity
2.14 Peptide and Protein Drugs: Issues and Solutions
2.15 Peptidomimetic and Nonpeptide Drug Discovery: Receptor, Protease, and Signal Transduction Therapeutic Targets
2.16 Bioisosterism
2.17 Chiral Drug Discovery and Development – From Concept Stage to Market Launch
2.18 Promiscuous Ligands
Targets
2.19 Diversity versus Focus in Choosing Targets and Therapeutic Areas
2.20 G Protein-Coupled Receptors
2.21 Ion Channels – Voltage Gated
2.22 Ion Channels – Ligand Gated
2.23 Phosphodiesterases
2.24 Protein Kinases and Protein Phosphatases in Signal Transduction Pathways
2.25 Nuclear Hormone Receptors
2.26 Nucleic Acids (Deoxyribonucleic Acid and Ribonucleic Acid)
2.27 Redox Enzymes
